FCN-338

Fochon Pharmaceuticals, Ltd. · Phase 1 active Small molecule

At a glance

Generic name	FCN-338
Sponsor	Fochon Pharmaceuticals, Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms (PHASE2)
A Study of FCN-338 in Patients With Chronic CLL/SLL (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FCN-338 CI brief — competitive landscape report
FCN-338 updates RSS · CI watch RSS
Fochon Pharmaceuticals, Ltd. portfolio CI